Compare ASTE & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | HROW |
|---|---|---|
| Founded | 1972 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2003 | N/A |
| Metric | ASTE | HROW |
|---|---|---|
| Price | $55.80 | $43.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $66.00 | ★ $69.86 |
| AVG Volume (30 Days) | 199.3K | ★ 836.2K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 784.21 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.72 | $31.62 |
| Revenue Next Year | $5.44 | $50.77 |
| P/E Ratio | $918.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.83 | $28.54 |
| 52 Week High | $65.69 | $54.98 |
| Indicator | ASTE | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 60.44 |
| Support Level | $55.74 | $40.56 |
| Resistance Level | $63.89 | $44.50 |
| Average True Range (ATR) | 2.28 | 2.13 |
| MACD | -0.39 | 0.18 |
| Stochastic Oscillator | 20.24 | 52.78 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.